Selected research
Industry Research
Medications for Treating Alcohol Dependence Industry Research Report 2026
Market perspective
The global Medications for Treating Alcohol Dependence market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Medications for Treating Alcohol Dependence market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Medications for Treating Alcohol Dependence market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Medications for Treating Alcohol Dependence market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Medications for Treating Alcohol Dependence include Teva, Sun Pharmaceutical Industries, Merck Group, Mylan, Zydus Pharmaceuticals, Glenmark Pharmaceuticals, Beijing Wellso Pharmaceutical Co, Taj Pharmaceuticals and TAGI Pharma Inc., among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Medications for Treating Alcohol Dependence market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Medications for Treating Alcohol Dependence.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Medications for Treating Alcohol Dependence Market by Company
Teva
Sun Pharmaceutical Industries
Merck Group
Mylan
Zydus Pharmaceuticals
Glenmark Pharmaceuticals
Beijing Wellso Pharmaceutical Co
Taj Pharmaceuticals
TAGI Pharma Inc.
Rusan Pharma Ltd
Lundbeck
Alvogen
Alkermes Inc
Medications for Treating Alcohol Dependence Segment by Type
Disulfiram
Naltrexone
Acamprosate
Other
Medications for Treating Alcohol Dependence Segment by Application
Clinic
Hospital
Retail Pharmacies
Rehabilitation Institutions
Medications for Treating Alcohol Dependence Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Medications for Treating Alcohol Dependence market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Medications for Treating Alcohol Dependence and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Medications for Treating Alcohol Dependence.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Medications for Treating Alcohol Dependence companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Disulfiram
- Naltrexone
- Acamprosate
- Other
Applications
- Clinic
- Hospital
- Retail Pharmacies
- Rehabilitation Institutions
Companies covered
- Teva
- Sun Pharmaceutical Industries
- Merck Group
- Mylan
- Zydus Pharmaceuticals
- Glenmark Pharmaceuticals
- Beijing Wellso Pharmaceutical Co
- Taj Pharmaceuticals
- TAGI Pharma Inc.
- Rusan Pharma Ltd
- Lundbeck
- Alvogen
- Alkermes Inc
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Medications for Treating Alcohol Dependence by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Disulfiram
- 2.2.3 Naltrexone
- 2.2.4 Acamprosate
- 2.2.5 Other
- 2.3 Medications for Treating Alcohol Dependence by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Clinic
- 2.3.3 Hospital
- 2.3.4 Retail Pharmacies
- 2.3.5 Rehabilitation Institutions
- 2.4 Assumptions and Limitations
3 Medications for Treating Alcohol Dependence Breakdown Data by Type
- 3.1 Global Medications for Treating Alcohol Dependence Historic Market Size by Type (2021-2026)
- 3.2 Global Medications for Treating Alcohol Dependence Forecasted Market Size by Type (2027-2032)
4 Medications for Treating Alcohol Dependence Breakdown Data by Application
- 4.1 Global Medications for Treating Alcohol Dependence Historic Market Size by Application (2021-2026)
- 4.2 Global Medications for Treating Alcohol Dependence Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Medications for Treating Alcohol Dependence Market Perspective (2021-2032)
- 5.2 Global Medications for Treating Alcohol Dependence Growth Trends by Region
- 5.2.1 Global Medications for Treating Alcohol Dependence Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Medications for Treating Alcohol Dependence Historic Market Size by Region (2021-2026)
- 5.2.3 Medications for Treating Alcohol Dependence Forecasted Market Size by Region (2027-2032)
- 5.3 Medications for Treating Alcohol Dependence Market Dynamics
- 5.3.1 Medications for Treating Alcohol Dependence Industry Trends
- 5.3.2 Medications for Treating Alcohol Dependence Market Drivers
- 5.3.3 Medications for Treating Alcohol Dependence Market Challenges
- 5.3.4 Medications for Treating Alcohol Dependence Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Medications for Treating Alcohol Dependence Players by Revenue
- 6.1.1 Global Top Medications for Treating Alcohol Dependence Players by Revenue (2021-2026)
- 6.1.2 Global Medications for Treating Alcohol Dependence Revenue Market Share by Players (2021-2026)
- 6.2 Global Medications for Treating Alcohol Dependence Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Medications for Treating Alcohol Dependence Head Office and Area Served
- 6.4 Global Medications for Treating Alcohol Dependence Players, Product Type & Application
- 6.5 Global Medications for Treating Alcohol Dependence Manufacturers Established Date
- 6.6 Global Medications for Treating Alcohol Dependence Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Medications for Treating Alcohol Dependence Market Size (2021-2032)
- 7.2 North America Medications for Treating Alcohol Dependence Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Medications for Treating Alcohol Dependence Market Size by Country (2021-2026)
- 7.4 North America Medications for Treating Alcohol Dependence Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Medications for Treating Alcohol Dependence Market Size (2021-2032)
- 8.2 Europe Medications for Treating Alcohol Dependence Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Medications for Treating Alcohol Dependence Market Size by Country (2021-2026)
- 8.4 Europe Medications for Treating Alcohol Dependence Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Medications for Treating Alcohol Dependence Market Size (2021-2032)
- 9.2 Asia-Pacific Medications for Treating Alcohol Dependence Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Medications for Treating Alcohol Dependence Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Medications for Treating Alcohol Dependence Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Medications for Treating Alcohol Dependence Market Size (2021-2032)
- 10.2 South America Medications for Treating Alcohol Dependence Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Medications for Treating Alcohol Dependence Market Size by Country (2021-2026)
- 10.4 South America Medications for Treating Alcohol Dependence Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Medications for Treating Alcohol Dependence Market Size (2021-2032)
- 11.2 Middle East & Africa Medications for Treating Alcohol Dependence Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Medications for Treating Alcohol Dependence Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Medications for Treating Alcohol Dependence Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Teva
- 12.1.1 Teva Company Information
- 12.1.2 Teva Business Overview
- 12.1.3 Teva Revenue in Medications for Treating Alcohol Dependence Business (2021-2026)
- 12.1.4 Teva Medications for Treating Alcohol Dependence Product Portfolio
- 12.1.5 Teva Recent Developments
- 12.2 Sun Pharmaceutical Industries
- 12.2.1 Sun Pharmaceutical Industries Company Information
- 12.2.2 Sun Pharmaceutical Industries Business Overview
- 12.2.3 Sun Pharmaceutical Industries Revenue in Medications for Treating Alcohol Dependence Business (2021-2026)
- 12.2.4 Sun Pharmaceutical Industries Medications for Treating Alcohol Dependence Product Portfolio
- 12.2.5 Sun Pharmaceutical Industries Recent Developments
- 12.3 Merck Group
- 12.3.1 Merck Group Company Information
- 12.3.2 Merck Group Business Overview
- 12.3.3 Merck Group Revenue in Medications for Treating Alcohol Dependence Business (2021-2026)
- 12.3.4 Merck Group Medications for Treating Alcohol Dependence Product Portfolio
- 12.3.5 Merck Group Recent Developments
- 12.4 Mylan
- 12.4.1 Mylan Company Information
- 12.4.2 Mylan Business Overview
- 12.4.3 Mylan Revenue in Medications for Treating Alcohol Dependence Business (2021-2026)
- 12.4.4 Mylan Medications for Treating Alcohol Dependence Product Portfolio
- 12.4.5 Mylan Recent Developments
- 12.5 Zydus Pharmaceuticals
- 12.5.1 Zydus Pharmaceuticals Company Information
- 12.5.2 Zydus Pharmaceuticals Business Overview
- 12.5.3 Zydus Pharmaceuticals Revenue in Medications for Treating Alcohol Dependence Business (2021-2026)
- 12.5.4 Zydus Pharmaceuticals Medications for Treating Alcohol Dependence Product Portfolio
- 12.5.5 Zydus Pharmaceuticals Recent Developments
- 12.6 Glenmark Pharmaceuticals
- 12.6.1 Glenmark Pharmaceuticals Company Information
- 12.6.2 Glenmark Pharmaceuticals Business Overview
- 12.6.3 Glenmark Pharmaceuticals Revenue in Medications for Treating Alcohol Dependence Business (2021-2026)
- 12.6.4 Glenmark Pharmaceuticals Medications for Treating Alcohol Dependence Product Portfolio
- 12.6.5 Glenmark Pharmaceuticals Recent Developments
- 12.7 Beijing Wellso Pharmaceutical Co
- 12.7.1 Beijing Wellso Pharmaceutical Co Company Information
- 12.7.2 Beijing Wellso Pharmaceutical Co Business Overview
- 12.7.3 Beijing Wellso Pharmaceutical Co Revenue in Medications for Treating Alcohol Dependence Business (2021-2026)
- 12.7.4 Beijing Wellso Pharmaceutical Co Medications for Treating Alcohol Dependence Product Portfolio
- 12.7.5 Beijing Wellso Pharmaceutical Co Recent Developments
- 12.8 Taj Pharmaceuticals
- 12.8.1 Taj Pharmaceuticals Company Information
- 12.8.2 Taj Pharmaceuticals Business Overview
- 12.8.3 Taj Pharmaceuticals Revenue in Medications for Treating Alcohol Dependence Business (2021-2026)
- 12.8.4 Taj Pharmaceuticals Medications for Treating Alcohol Dependence Product Portfolio
- 12.8.5 Taj Pharmaceuticals Recent Developments
- 12.9 TAGI Pharma Inc.
- 12.9.1 TAGI Pharma Inc. Company Information
- 12.9.2 TAGI Pharma Inc. Business Overview
- 12.9.3 TAGI Pharma Inc. Revenue in Medications for Treating Alcohol Dependence Business (2021-2026)
- 12.9.4 TAGI Pharma Inc. Medications for Treating Alcohol Dependence Product Portfolio
- 12.9.5 TAGI Pharma Inc. Recent Developments
- 12.10 Rusan Pharma Ltd
- 12.10.1 Rusan Pharma Ltd Company Information
- 12.10.2 Rusan Pharma Ltd Business Overview
- 12.10.3 Rusan Pharma Ltd Revenue in Medications for Treating Alcohol Dependence Business (2021-2026)
- 12.10.4 Rusan Pharma Ltd Medications for Treating Alcohol Dependence Product Portfolio
- 12.10.5 Rusan Pharma Ltd Recent Developments
- 12.11 Lundbeck
- 12.11.1 Lundbeck Company Information
- 12.11.2 Lundbeck Business Overview
- 12.11.3 Lundbeck Revenue in Medications for Treating Alcohol Dependence Business (2021-2026)
- 12.11.4 Lundbeck Medications for Treating Alcohol Dependence Product Portfolio
- 12.11.5 Lundbeck Recent Developments
- 12.12 Alvogen
- 12.12.1 Alvogen Company Information
- 12.12.2 Alvogen Business Overview
- 12.12.3 Alvogen Revenue in Medications for Treating Alcohol Dependence Business (2021-2026)
- 12.12.4 Alvogen Medications for Treating Alcohol Dependence Product Portfolio
- 12.12.5 Alvogen Recent Developments
- 12.13 Alkermes Inc
- 12.13.1 Alkermes Inc Company Information
- 12.13.2 Alkermes Inc Business Overview
- 12.13.3 Alkermes Inc Revenue in Medications for Treating Alcohol Dependence Business (2021-2026)
- 12.13.4 Alkermes Inc Medications for Treating Alcohol Dependence Product Portfolio
- 12.13.5 Alkermes Inc Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst